SLC12A9

Across TCGA pan-cancer cohorts, SLC12A9 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SLC12A9’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SLC12A9 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC12A9 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

HNSC, LSCC, and COAD are the cancer types where SLC12A9 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC12A9 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.240	<.001	9	view →
LSCC	Female	II,III,IV	−0.491	<.001	8	view →
COAD	Female	III,IV	+0.220	<.001	7	view →
PDAC	Male	All	+0.540	<.001	6	view →
LUAD	Male	All	−0.163	<.001	4	view →
CCRCC	All	All	+0.097	.018	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SLC12A9–HNSC

Open the HNSC breakdown →